Control Bionics Ltd (CBL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Control Bionics Ltd (CBL) has a cash flow conversion efficiency ratio of -0.559x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-3.53 Million ≈ $-2.49 Million USD) by net assets (AU$6.31 Million ≈ $4.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CBL stock market capitalisation for the company's overall valuation and market capitalisation.
Control Bionics Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Control Bionics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Control Bionics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Control Bionics Ltd ranked by their cash flow conversion efficiency. See Control Bionics Ltd cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NORTH PEAK RESOURCES LTD.
F:B9TN
|
-0.078x |
|
BonTerra Resources Inc
V:BTR
|
0.894x |
|
Radiant Innovation
TWO:3373
|
0.014x |
|
Radiopharm Theranostics Limited American Depositary Shares
NASDAQ:RADX
|
-1.437x |
|
Plastofil -L
TA:PPIL
|
0.042x |
|
Smartlink Holdings Limited
NSE:SMARTLINK
|
0.022x |
|
Aguia Resources Ltd
AU:AGR
|
-0.050x |
|
KB Autosys Co. Ltd
KQ:024120
|
-0.009x |
Annual Cash Flow Conversion Efficiency for Control Bionics Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of Control Bionics Ltd from 2017 to 2025. View CBL share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | AU$6.31 Million ≈ $4.47 Million |
AU$-5.75 Million ≈ $-4.07 Million |
-0.911x | -17.50% |
| 2024-12-31 | AU$5.51 Million ≈ $3.90 Million |
AU$-4.27 Million ≈ $-3.02 Million |
-0.775x | +1.11% |
| 2023-12-31 | AU$6.27 Million ≈ $4.43 Million |
AU$-4.91 Million ≈ $-3.48 Million |
-0.784x | -23.18% |
| 2022-12-31 | AU$7.12 Million ≈ $5.04 Million |
AU$-4.53 Million ≈ $-3.20 Million |
-0.636x | -10.15% |
| 2021-12-31 | AU$11.92 Million ≈ $8.44 Million |
AU$-6.89 Million ≈ $-4.87 Million |
-0.578x | -148.41% |
| 2020-12-31 | AU$17.16 Million ≈ $12.14 Million |
AU$-3.99 Million ≈ $-2.82 Million |
-0.233x | -441.59% |
| 2019-12-31 | AU$20.13 Million ≈ $14.24 Million |
AU$-864.05K ≈ $-611.37K |
-0.043x | +88.85% |
| 2018-12-31 | AU$5.05 Million ≈ $3.58 Million |
AU$-1.95 Million ≈ $-1.38 Million |
-0.385x | -141.49% |
| 2017-12-31 | AU$6.09 Million ≈ $4.31 Million |
AU$-970.84K ≈ $-686.93K |
-0.159x | -- |
About Control Bionics Ltd
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electroni… Read more